Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

Open access
Machiels, Jean-Pascal H., Henry, Stéphanie, Zanetta, Sylvie, Kaminsky, Marie-Christine, Michoux, Nicolas, Rommel, Denis, Schmitz, Sandra, Bompas, Emmanuelle, Dillies, Anne-Françoise, Faivre, Sandrine, Moxhon, Anne, Duprez, Thierry, Guigay, Joel · 2010 · Journal of Clinical Oncology

Abstract

Purpose: To assess the efficacy and toxicity of sunitinib monotherapy in palliative squamous cell carcinoma of the head and neck (SCCHN). Patients and Methods: Thirty-eight patients with SCCHN having evidence of progressive disease (PD) were treated with sunitinib 37.5 mg/d given continuously until PD or unacceptable toxicity. The primary end point was the rate of disease control, defined as stable disease (SD) or partial response (PR) at 6 to 8 weeks after treatment initiation (two-stage design, Simon). Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was performed in a subset of patients before and 6 to 8 weeks after treatment. The volume transfer constant of the contrast agent (K trans) was used to measure changes in the microcirculation blood flow and endothelial permeability of the tumor. Results: A PR was observed in one patient, SD in 18, and PD in 19 (Response Evaluation Criteria in Solid Tumors [RECIST]), resulting in a disease control rate of 50%. Among the 18 patients with SD, there were five unconfirmed PRs and six additional minor responses. A significant decrease in K trans was seen in three of the four patients who received DCE-MRI monitoring. Grade 5 head and neck bleeds occurred in four patients. Local complications, including the appearance or worsening of tumor skin ulceration or tumor fistula, were recorded in 15 patients. Conclusion: Sunitinib demonstrated modest activity in palliative SSCHN. The severity of some of the complications highlights the importance of improved patient selection for future studies with sunitinib in head and neck cancer. Sunitinib should not be used outside clinical trials in SSCHN.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.8584

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 171

Metadata

Authors
Machiels, J.-P. H., Henry, S., Zanetta, S., Kaminsky, M.-C., Michoux, N., Rommel, D., Schmitz, S., Bompas, E., Dillies, A.-F., Faivre, S., Moxhon, A., Duprez, T., & Guigay, J.
Venue
Journal of Clinical Oncology
Published
2010-01-01
Volume
28
Issue
1
Pages
21-28
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2163918907
Cited by
171
References
1
FWCI
16.24
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01. https://app.cochat.ai/papers/10.1200/jco.2009.23.8584
The paper
Machiels, J.-P. H., Henry, S., Zanetta, S., Kaminsky, M.-C., Michoux, N., Rommel, D., Schmitz, S., Bompas, E., Dillies, A.-F., Faivre, S., Moxhon, A., Duprez, T., & Guigay, J. (2010). Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.23.8584

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.